pyrazines has been researched along with 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonnet, PA; Crilley, TK; Wanstall, JC | 1 |
| Fuchikami, C; Honda, Y; Kosugi, K; Kuramoto, K; Kuwano, K; Numakura, Y | 1 |
2 other study(ies) available for pyrazines and 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
| Article | Year |
|---|---|
Vasorelaxant effects of SCA40 (a phosphodiesterase III inhibitor) in pulmonary vascular preparations in rats.
Topics: 1-Methyl-3-isobutylxanthine; 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 3; Guinea Pigs; Imidazoles; Male; Milrinone; Muscle, Smooth, Vascular; Parasympatholytics; Phosphodiesterase Inhibitors; Potassium Channel Blockers; Pulmonary Artery; Pyrazines; Pyridones; Rats; Rats, Wistar; Trachea; Vasodilation; Vasodilator Agents | 1998 |
The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetamides; Animals; Cell Proliferation; Collagen Type I; Disease Models, Animal; Heart Ventricles; Hemodynamics; Hypertrophy, Right Ventricular; Hypoxia; Indoles; Lung; Male; Pulmonary Arterial Hypertension; Pyrazines; Pyrroles; Rats, Sprague-Dawley; Receptors, Epoprostenol; Systole; Vascular Remodeling | 2020 |